NASDAQ:MDCO - The Medicines Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$33.66 +0.10 (+0.30 %)
(As of 09/18/2018 04:00 PM ET)
Previous Close$33.56
Today's Range$33.37 - $34.50
52-Week Range$24.45 - $41.57
Volume602,500 shs
Average Volume1.03 million shs
Market Capitalization$2.51 billion
P/E Ratio-4.02
Dividend YieldN/A
Beta0.77
The Medicines logoThe Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States. It primarily focuses on developing Inclisiran, a lipid-lowering drug to reduce LDL-cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or cardiovascular risk-equivalents. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

Receive MDCO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDCO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MDCO
CUSIP58468810
Phone973-290-6000

Debt

Debt-to-Equity Ratio31.23
Current Ratio2.60
Quick Ratio2.55

Price-To-Earnings

Trailing P/E Ratio-4.02
Forward P/E Ratio-13.36
P/E GrowthN/A

Sales & Book Value

Annual Sales$44.79 million
Price / Sales55.45
Cash FlowN/A
Price / CashN/A
Book Value$0.34 per share
Price / Book99.00

Profitability

EPS (Most Recent Fiscal Year)($8.40)
Net Income$-708,370,000.00
Net Margins-668.93%
Return on Equity-394.33%
Return on Assets-33.65%

Miscellaneous

Employees170
Outstanding Shares73,790,000
Market Cap$2.51 billion

The Medicines (NASDAQ:MDCO) Frequently Asked Questions

What is The Medicines' stock symbol?

The Medicines trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines' earnings last quarter?

The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings results on Wednesday, August, 1st. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.30. The firm had revenue of $1.67 million for the quarter, compared to analysts' expectations of $7.20 million. The Medicines had a negative net margin of 668.93% and a negative return on equity of 394.33%. The Medicines's revenue was down 84.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.72) earnings per share. View The Medicines' Earnings History.

When is The Medicines' next earnings date?

The Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, October, 24th 2018. View Earnings Estimates for The Medicines.

What price target have analysts set for MDCO?

7 analysts have issued 1 year price targets for The Medicines' stock. Their predictions range from $45.00 to $85.00. On average, they anticipate The Medicines' share price to reach $53.8571 in the next twelve months. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Price Targets for The Medicines.

What is the consensus analysts' recommendation for The Medicines?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Medicines in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for The Medicines.

What are Wall Street analysts saying about The Medicines stock?

Here are some recent quotes from research analysts about The Medicines stock:
  • 1. According to Zacks Investment Research, "The Medicines Company reported mixed second-quarter results, beating earnings estimates while missing the same for revenues. The company’s pipeline boasts a potential blockbuster candidate, inclisiran, being developed for hypercholesterolemia. Moreover, the company implemented a workforce lay-off last year for better alignment of its cost and structure. We are also encouraged by The Medicines Co.’s regular divestiture of non-core products. This will optimize its capital structure and enhance its liquidity position. However, with Angiomax sales eroding due to presence of generics, the company’s ability to successfully develop and bring in new products to the market is highly important for growth. Any regulatory setback would weigh heavily on the stock. Shares of the company have outperformed the industry so far this year." (8/7/2018)
  • 2. Chardan Capital analysts commented, "We found particularly notable: (1) MDCO completing recruitment in just 11 weeks for its 1500-patient ORION-11 pivotal phase III trial of siRNA- based PSCK9 synthesis inhibitor inclisiran (partnered with Alnylam, Buy) and may thus have its first top-line pivotal results in 3Q19, (2) the confirmation commercial scale manufacturing for inclisiran has been achieved, and (3) new inclisiran efficacy data in HoFH to us suggesting efficacy beyond mAb PCSK9 inhibitors. With inclisiran to us having clear momentum towards 2H19E pivotal data and what we expect will be $4.7 billion in 2030E peak sales, we make MDCO a Chardan Top Pick for 2018." (1/24/2018)

Who are some of The Medicines' key competitors?

Who are The Medicines' key executives?

The Medicines' management team includes the folowing people:
  • Dr. Clive A. Meanwell, CEO & Director (Age 60)
  • Mr. Stephen M. Rodin J.D., Exec. VP, Gen. Counsel & Sec. (Age 42)
  • Mr. Christopher T. Cox, Chief Corp. Devel. Officer and Exec. VP (Age 53)
  • Mr. William B. O'Connor, Special Advisor to the Chief Exec. Officer (Age 59)
  • Mr. Christopher Visioli, CFO & Treasurer (Age 42)

Has The Medicines been receiving favorable news coverage?

Media stories about MDCO stock have trended somewhat positive on Tuesday, according to Accern. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. The Medicines earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news articles about the company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for The Medicines.

Who are The Medicines' major shareholders?

The Medicines' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.83%), PointState Capital LP (5.44%), Iridian Asset Management LLC CT (2.86%), Pinnacle Associates Ltd. (1.28%), Northern Trust Corp (1.23%) and OppenheimerFunds Inc. (0.96%). Company insiders that own The Medicines stock include Alexander J Denner, Armin M Kessler, Christopher T Cox, Clive Meanwell, Fredric N Eshelman, Melvin K Spigelman, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines.

Which major investors are selling The Medicines stock?

MDCO stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Iridian Asset Management LLC CT, FMR LLC, California Public Employees Retirement System, Piedmont Investment Advisors LLC, Creative Planning, Pinebridge Investments L.P. and Municipal Employees Retirement System of Michigan. Company insiders that have sold The Medicines company stock in the last year include Armin M Kessler, Clive Meanwell, Melvin K Spigelman and William Crouse. View Insider Buying and Selling for The Medicines.

Which major investors are buying The Medicines stock?

MDCO stock was bought by a variety of institutional investors in the last quarter, including PointState Capital LP, Advisors Asset Management Inc., American Century Companies Inc., Granahan Investment Management Inc. MA, Bailard Inc., Canada Pension Plan Investment Board, Trexquant Investment LP and Family Management Corp. Company insiders that have bought The Medicines stock in the last two years include Alexander J Denner, Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines.

How do I buy shares of The Medicines?

Shares of MDCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is The Medicines' stock price today?

One share of MDCO stock can currently be purchased for approximately $33.66.

How big of a company is The Medicines?

The Medicines has a market capitalization of $2.51 billion and generates $44.79 million in revenue each year. The company earns $-708,370,000.00 in net income (profit) each year or ($8.40) on an earnings per share basis. The Medicines employs 170 workers across the globe.

How can I contact The Medicines?

The Medicines' mailing address is 8 SYLVAN WAY, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-290-6000 or via email at [email protected]


MarketBeat Community Rating for The Medicines (NASDAQ MDCO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  408 (Vote Outperform)
Underperform Votes:  284 (Vote Underperform)
Total Votes:  692
MarketBeat's community ratings are surveys of what our community members think about The Medicines and other stocks. Vote "Outperform" if you believe MDCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDCO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel